Prior to joining SIgma-Aldrich, David was CEO and President of ProteoPlex, Inc., a seed stage spinout focusing on functional genomics. He founded ProteoPlex, Inc. in 2001 and led the St. Louis-based company through its product development and final acquisition by EMD Biosciences (Merck KGaA).
In 1992, David founded Genome Systems, Inc. in St. Louis which provided the scientific community with access to genome project-related technologies. He stayed at the helm of the organization during its acquisition in 1996 by the Incyte Corporation, based in Palo Alto, CA, and was promoted to Senior Vice President and leader of the organization’s St. Louis operations, where he grew the staff to more than 250 people. During his tenure at Incyte, his responsibilities expanded and included the management of the $150M Genomic Business Unit. This responsibility included overseeing the management of 700 employees, as well as managing the strategic planning, product marketing and research and development strategy of the unit.
David earned a doctorate degree in Molecular Biology and a bachelor’s degree in Biology from Emory University in Atlanta. He completed a postdoctoral fellowship at Washington University in St. Louis in the Drosophila Genome project and a postdoctoral fellowship at Monsanto Corporation. He is a board member of the center of Emerging Technologies, the St. Louis Academy of Science, Washington University National Research Advisory Council, and The advisory Council of the Biomedical Engineering Department of Washington University, as well as a number of start up biotech companies.